Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Diese Tech-Aktie könnte Ihr Portfolio revolutionieren – und die nächste große Sicherheitslücke schließen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14V4E | ISIN: BE0974283153 | Ticker-Symbol: N/A
Frankfurt
29.04.24
08:22 Uhr
0,176 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
MITHRA PHARMACEUTICALS SA Chart 1 Jahr

Aktuelle News zur MITHRA PHARMACEUTICALS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.09.2024355The following instruments on Boerse Frankfurt do have their last trading day on 26.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.09.2024ISIN NameDE000CZ45W08 COBA...
► Artikel lesen
12.06.Gedeon Richter Agrees to Acquire Mithra Pharmaceuticals Assets for EUR 175 mln33
28.05.Mithra Pharmaceuticals postpones its annual general meeting9
MITHRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
03.05.Mithra Pharmaceuticals enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process451Liege, Belgium, 3 May 2024 - 17:30 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces that, after diligent evaluation of several binding offers, Mithra...
► Artikel lesen
29.04.XFRA 1TM: AUSSETZUNG/SUSPENSION413DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMITHRA PHARMACEUTIC.AIW...
► Artikel lesen
22.04.Mithra Pharmaceuticals secures court protection measures to advance monetization process298Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization.Approval...
► Artikel lesen
08.03.Mithra Pharmaceuticals reports full year 2023 financial results852Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from...
► Artikel lesen
05.03.Mithra Pharmaceuticals initiates monetization process, receives bridge loan from existing lenders652Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra...
► Artikel lesen
05.03.Mithra Pharmaceuticals announces changes to its executive management722Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 - 07:00 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces the termination...
► Artikel lesen
29.02.Mithra Pharmaceuticals: DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase570DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
► Artikel lesen
15.02.Mithra Pharmaceuticals sells shares in Mayne Pharma712Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of...
► Artikel lesen
06.02.Mithra Pharmaceuticals updates on cash position626Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with stakeholdersMithra...
► Artikel lesen
21.12.23Mithra Pharmaceuticals and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel1.546Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on...
► Artikel lesen
20.12.23Mithra Pharmaceuticals Completes Pediatric Study of ESTELLE® in Adolescent Patients649Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra's commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
► Artikel lesen
18.12.23Mithra Pharmaceuticals Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial444Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3...
► Artikel lesen
04.12.23Mithra Pharmaceuticals and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China464Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter...
► Artikel lesen
30.11.23Mithra Pharmaceuticals receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States596Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to...
► Artikel lesen
28.11.23Mithra Pharmaceuticals to hold five presentations on key role of estrogens in women's health, including Estetrol (E4), at the ESG Congress in Amsterdam455Mithra to hold five presentations on key role of estrogens in women's health, including Estetrol (E4), at the ESG Congress in Amsterdam Five abstracts on the positive effect of E4 accepted...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten